Here, we report the use of a multi-target kinase inhibitor, GSK2606414 or 414, to treat tau transgenic mice in a proof-of-concept study to evaluate whether such strategies can mitigate the early negative outcomes of tauopathy. Here, MAPT is linked to tauopathy.